Amphastar France Pharmaceuticals

Company snapshot

Amphastar Pharmaceuticals is a recognized pharmaceutical company that uses state-of-the-art, cGMP-compliant facilities to develop, manufacture, and market biopharmaceutical injectable, intranasal, and inhalation products. In addition to the Corporate Headquarters, Amphastar has five manufacturing facilities in the United States, China, and Europe, along with a state-of-the-art New Drug Research Ce

• 8 approved product(s) across US/EU regulatory metadata.
• 18 active pipeline program(s) linked via ClinicalTrials.gov.
• 15 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Amphastar France Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Amphastar France Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   API-E004-CL-A — Phase 2

2. Jun 8, 2026 Clinical update

   API-E004-CL-B4 — Phase 2

3. Jun 8, 2026 Clinical update

   Epinephrine Inhalation Aerosol, HFA — Phase 2

4. Jun 8, 2026 Clinical update

   epinephrine inhalation aerosol — Phase 3

5. Jun 8, 2026 Clinical update

   Epinephrine (0.125 mg/inhalation) — Approved

View all clinical trial activity →

• What is Amphastar France Pharmaceuticals?

  AMPHASTAR FRANCE PHARMACEUTICALS is a pharma organization headquartered in Rancho Cucamonga, FR. It trades on NYSE under ticker AMPH. Primary therapeutic focus areas include Asthma, Pharmacokinetics, Allergic Skin Reaction. NovaPharmaNews links 18 clinical program(s), 6 drug prof

• Is Amphastar France Pharmaceuticals publicly traded?

  Yes. Amphastar France Pharmaceuticals is listed with ticker AMPH on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Amphastar France Pharmaceuticals develop or market?

  We link 15 drug profile(s) where Amphastar France Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/amphastar-pharmaceuticals#company-drugs.

• What are the latest developments for Amphastar France Pharmaceuticals?

  In the last 12 months our linked public records show 18 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does Amphastar France Pharmaceuticals focus on?

  Amphastar France Pharmaceuticals focuses on Asthma, Pharmacokinetics, Allergic Skin Reaction based on our analysis of their pipeline programs and drug development activities.